We serve Chemical Name:N-2-Trifluoromethylphenyl 4-boronobenzamide CAS:913835-42-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-2-Trifluoromethylphenyl 4-boronobenzamide
CAS.NO:913835-42-4
Synonyms:[4-[[2-(trifluoromethyl)phenyl]carbamoyl]phenyl]boronic acid
Molecular Formula:C14H11BF3NO3
Molecular Weight:309.04800
HS Code:2931900090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.4g/cm3
Index of Refraction:1.563
PSA:69.56000
Exact Mass:309.07800
LogP:1.71050
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like [4-[[2-(trifluoromethyl)phenyl]carbamoyl]phenyl]boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[4-[[2-(trifluoromethyl)phenyl]carbamoyl]phenyl]boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[4-[[2-(trifluoromethyl)phenyl]carbamoyl]phenyl]boronic acid Use and application,[4-[[2-(trifluoromethyl)phenyl]carbamoyl]phenyl]boronic acid technical grade,usp/ep/jp grade.
Related News: What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. N-2-Trifluoromethylphenyl 4-boronobenzamide manufacturer What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. N-2-Trifluoromethylphenyl 4-boronobenzamide supplier The Branchburg factory first came under FDA scrutiny in late 2019, when agency inspectors began to document numerous quality control problems. By March, 2020, the FDA had deemed the manufacturing issues as “Official Action Indicated,” its most serious category of violation. N-2-Trifluoromethylphenyl 4-boronobenzamide vendor What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. N-2-Trifluoromethylphenyl 4-boronobenzamide factory Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.
